JOINING JACK — grant history
Latest income
£890k
Grants listed (FY2024)
0
Listed grants total
—
Accounts grants total
£531k
extracted from its FY2024 accounts
What this funder supports
Where grantees operate
- Northern Ireland
- Scotland
- Throughout England And Wales
What changed: FY2022 → FY2023
| Change | Grantee | FY2022 | FY2023 |
|---|---|---|---|
| new | Beveseesn BioPharma Inc, USA | — | £400k |
| down | Solid GT, Boston, USA | £1.3m | £400k |
| not listed | Reveragen BioPharma Inc, USA | £312k | — |
| not listed | Summit Corporation, Oxford, UK | £100k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Beveseesn BioPharma Inc, USA | FY2023 | £400k | vee-15, Phase 1 Ginical Trial |
| Solid GT, Boston, USA | FY2023 | £400k | sene therapy |
| University Children’s Hospital Basel | FY2023 | £230k | Tr = study for Or |
| University of Geneva | FY2023 | £200k | Preclinical study of the combination of tamoxifen, L-citrulline and metformin |
| EVOX Therapeutics | FY2023 | £200k | New ways of delivering Gene |
| University Children’s Hospital Basel | FY2023 | £195k | Tamoxifen Clinical Trial |
| University of Florida | FY2023 | £185k | Immunology Grant |
| Newcastle University | FY2023 | £140k | DMD Care UK |
| University of Minnesota | FY2023 | £140k | Stem cells |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £127k | ST4 Neuromuscular Clinical |
| Royal Preston Hospital | FY2023 | £118k | Hydrotherapy Clinical Trial |
| Akashi Therapeutics, USA | FY2023 | £100k | Phase1/2 Clinical trial of HT-100 |
| University Children’s Hospital Basel | FY2023 | £97k | Tamoxifen Project Manager |
| University of Newcastle | FY2023 | £79k | |
| University of Glasgow | FY2023 | £75k | DMD Care Neuropsychiatrist |
| Freeman Hospital | FY2023 | £67k | Or John Bourke |
| Muscular Dystrophy Campaign | FY2023 | £55k | The Duchenne Forum, Supporting 8 |
| Whizz Kidz | FY2023 | £50k | Dream Chair development |
| The University of Western Australia | FY2023 | £50k | Taurine |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £46k | Physiotherapist |
| University of Liverpool | FY2023 | £36k | Elastase Inhibitors to Treat |
| University of Newcastle | FY2023 | £36k | Co-Funded Lectureship for a |
| Newcastle University | FY2023 | £33k | Antifibrotic/antiadipogenic drug |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £32k | Duchenne Clinical Research Nurse |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £31k | Neuromuscular Clinical Research |
| University of Sheffield | FY2023 | £31k | investigating soy products as a |
| University of Geneva | FY2023 | £25k | Repurposing Drugs |
| Agada Biosciences | FY2023 | £25k | Tackling fibrosis and muscle |
| Royal Victoria Infirmary, Newcastle | FY2023 | £23k | Duchenne Clinical Trial Nurse |
| Duke University | FY2023 | £20k | Biomarker Trial |
| Alder Hey | FY2023 | £14k | ow Heart Protection Study |
| University of Newcastle | FY2023 | £10k | Ferosis Or |
| University of Newcastle | FY2023 | £10k | Acute tranacec |
| University of Newcastle | FY2023 | £10k | Testosterone extension |
| Leiden University | FY2023 | £10k | Vitamin B3 |
| Newcastle University | FY2023 | £10k | Sout Trial |
| The University of Reading | FY2023 | £6k | Assessing the preclinical therapeutic impact of cannabidiol for DAD |
| Binghamton, the State University of New York | FY2023 | £1k | Immunology Grant Call Award |
| Solid GT, Boston, USA | FY2022 | £1.3m | Gene therapy |
| Reveragen BioPharma Inc, USA | FY2022 | £312k | VBP-15, Phase 1 Clinical Trial |
| University Children’s Hospital Basel | FY2022 | £230k | Open label extension study for Tamoxifen |
| University of Geneva | FY2022 | £200k | Preclinical study of the combination of tamoxifen, Lcitrulline and metformin |
| EVOX Therapeutics | FY2022 | £200k | New ways of delivering Gene Therapy |
| University Children’s Hospital Basel | FY2022 | £195k | Tamoxifen Clinical Trial |
| University of Florida | FY2022 | £185k | Immunology Grant |
| University of Minnesota | FY2022 | £140k | Stem Cells |
| Newcastle University | FY2022 | £140k | DMD Care UK |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £127k | ST4 Neuromuscular Clinical Research Doctor |
| Royal Preston Hospital | FY2022 | £118k | Hydrotherapy Clinical Trial |
| Summit Corporation, Oxford, UK | FY2022 | £100k | Developing biomarkers for Utrophin Modulators |
| University Children’s Hospital Basel | FY2022 | £97k | Tamoxifen Project Manager |
| University of Newcastle | FY2022 | £79k | TREAT-NMD DMD Co-Ordinator Role |
| Akashi Therapeutics, USA | FY2022 | £78k | Phase1/2 Clinical trial of HT-100 |
| University of Glasgow | FY2022 | £75k | DMD Care Neuropsychiatrist |
| Freeman Hospital | FY2022 | £67k | Understanding heart disease in DMD |
| Muscular Dystrophy Campaign | FY2022 | £55k | The Duchenne Forum, Supporting 8 basic research projects |
| The University of Western Australia | FY2022 | £50k | Taurine |
| Whizz Kidz | FY2022 | £50k | Dream Chair development |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £46k | Physiotherapist |
| University of Liverpool | FY2022 | £36k | Use of Elastase Inhibitors to Treat DMD |
| University of Newcastle | FY2022 | £36k | Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy |
| Newcastle University | FY2022 | £33k | Antifibrotic/antiadipogenic drug Fibrogenesis |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £32k | Duchenne Clinical Research Nurse |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £31k | F2 Neuromuscular Clinical Research Doctor |
| University of Sheffield | FY2022 | £31k | Investigating soy products as a treatment for DMD |
| University of Geneva | FY2022 | £25k | Repurposing Drugs |
| Agada Biosciences | FY2022 | £25k | Tackling fibrosis and muscle regeneration |
| Royal Victoria Infirmary, Newcastle | FY2022 | £23k | Duchenne Clinical Trial Nurse |
| Duke University | FY2022 | £20k | Biomarker Trial |
| Alder Hey | FY2022 | £14k | DMD Heart Protection Study |
| Leiden University | FY2022 | £10k | Vitamin B3 |
| University of Newcastle | FY2022 | £10k | Fibrosis |
| University of Newcastle | FY2022 | £10k | Adult NMCCC |
| University of Newcastle | FY2022 | £10k | Testosterone extension |
| Newcastle University | FY2022 | £10k | Splint Trial |
| The University of Reading | FY2022 | £6k | Assessing the preclinical therapeutic impact of cannabidiol for DMD |
| Binghamton, the State University of New York | FY2022 | £1k | Immunology Grant Call Award |